English

Report on Operations 2019: High Time-lapse growth

Report this content

Fourth quarter

  • Sales amounted to SEK 409 (320) million, corresponding to an increase of 28 percent in SEK. Sales increased by 21 percent in local currency whereof 11 percent comprised organic growth.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 160 (135) million, corresponding to a margin of 39 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million.
  • Net income amounted to SEK 96 (84) million, which gave earnings per share of SEK 0.89 (0.77).

Whole year 2019

  • Sales amounted to SEK 1 480 (1 151) million, corresponding to an increase of 29 percent in SEK. Sales increased by 22 percent in local currency whereof 12 percent comprised organic growth.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 587 (479) million, corresponding to a margin of 40 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 37 million.
  • Net income amounted to SEK 384 (311) million, which gave earnings per share of SEK 3.53 (2.85).

After the end of the period

  • The Board proposes a dividend of SEK 114 (92) million, corresponding to SEK 1.05 (0.85) per share.

Gothenburg, February 6, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

 

 

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on February 6, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags:

Interim report Vitrolife telephone conference interim report Mikael Engblom Thomas Axelsson

Subscribe

Documents & Links